Results 51 to 60 of about 2,655 (208)
Galcanezumab as a Treatment For The Prevention of Migraines [PDF]
, 2020 Objective: To determine the effectiveness of subcutaneous galcanezumab as a preventative treatment for chronic migraines via a systematic review. Methods: JAMA and PubMed databases were searched using the terms galcanezumab and migraines in order to ...
Brown, Jacob, Weedon, Chelsea
core +1 more source
Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients [PDF]
, 2023 Background Anti-CGRP monoclonal antibodies have shown notable effectiveness and tolerability in migraine patients; however, data on their use in elderly patients is still lacking, as clinical trials have implicit age restrictions and real-world evidence ...
Adell Ortega, Vanesa +32 more
core +1 more source
Cephalalgia Reports, 2021 Objective: The efficacy of galcanezumab was evaluated in patients with episodic cluster headache and history of preventive treatment failure. Methods: In the randomized, 8-week, double-blind study (CGAL), patients with episodic cluster headache received ...
Brian Plato +7 more
doaj +1 more source
A framework for decision making of migraine treatment with anti- CGRP monoclonal antibodies: a guide for real-world practice and public policies [PDF]
, 2020 Anti-CGRP monoclonal antibodies have been developed for migraine preventive treatment. There is evidence of good efficacy and safety of these medications; however, cost is a factor that interferes with the choice of treatment.
Dangoni Filho, Iron +3 more
core +2 more sources
Preventive CGRP-targeted therapies for chronic migraine with and without medication-overuse headache [PDF]
, 2023 Chronic migraine; Medication-overuse; Monoclonal antibodiesMigranya crònica; Abús de medicaments; Anticossos monoclonalsMigraña crónica; Abuso de medicamentos; Anticuerpos monoclonalesBackground: Calcitonin gene-related peptide (CGRP) targeted therapies
Alpuente Ruiz, Alicia +2 more
core +1 more source
Case reports: Could sexual dysfunction in women with migraine be a side effect of CGRP inhibition? [PDF]
BACKGROUND: The development and approval of antibodies targeting calcitonin gene-related peptide or its receptor mark a revolutionary era for preventive migraine treatment.
Al-Hassany, Linda +3 more
core +4 more sources
Mode and site of action of therapies targeting CGRP signaling [PDF]
, 2023 Calcitonin; Headache; MigraineCalcitonina; Dolor de cabeza; MigrañaCalcitonina; Mal de cap; MigranyaTargeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that ...
Braniste, Diana +5 more
core +1 more source
Canadian Journal of Health Technologies, 2022 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +2 more sources
The Journal of Headache and Pain, 2020 Background Migraine clinical profile may change with age, making it necessary to verify that migraine treatments are equally safe and effective in older patients. These analyses evaluated the effects of patient age on the pharmacokinetics (PK), efficacy,
Virginia L. Stauffer +7 more
doaj +1 more source
Reversible cerebral vasoconstriction syndrome: A narrative review
Headache: The Journal of Head and Face Pain, EarlyView.Abstract Objectives/Background This review summarizes current insights into Reversible cerebral vasoconstriction syndrome (RCVS) diagnosis, management, and outcomes. RCVS is a cerebrovascular disorder characterized by recurrent thunderclap headaches and transient segmental vasoconstriction of cerebral arteries, typically resolving within 3 months ...
Ícaro Araújo de Sousa +7 more
wiley +1 more source